Vanguard Group
JANX icon

Vanguard Group’s Janux Therapeutics JANX Stock Holding History

Vanguard Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$40.1M Buy
2,906,386
+489,282
+20% +$11.5M ﹤0.01% 2287
2025
Q3 		$59.1M Buy
2,417,104
+227,676
+10% +$5.54M ﹤0.01% 2080
2025
Q2 		$50.6M Sell
2,189,428
-89,232
-4% -$2.35M ﹤0.01% 2113
2025
Q1 		$61.5M Buy
2,278,660
+142,328
+7% +$5.37M ﹤0.01% 2006
2024
Q4 		$114M Buy
2,136,332
+288,402
+16% +$15.3M ﹤0.01% 1814
2024
Q3 		$84M Buy
1,847,930
+286,172
+18% +$12.4M ﹤0.01% 1951
2024
Q2 		$65.4M Buy
1,561,758
+203,798
+15% +$9.57M ﹤0.01% 2044
2024
Q1 		$51.1M Buy
1,357,960
+378,477
+39% +$8.24M ﹤0.01% 2158
2023
Q4 		$10.5M Buy
979,483
+37,202
+4% +$322K ﹤0.01% 2919
2023
Q3 		$9.5M Buy
942,281
+180,291
+24% +$2.08M ﹤0.01% 2918
2023
Q2 		$9.04M Sell
761,990
-10,665
-1% -$143K ﹤0.01% 3002
2023
Q1 		$9.35M Buy
772,655
+18,035
+2% +$300K ﹤0.01% 2973
2022
Q4 		$9.94M Sell
754,620
-5,854
-0.8% -$85.7K ﹤0.01% 2949
2022
Q3 		$10.3M Buy
760,474
+110,834
+17% +$1.48M ﹤0.01% 2940
2022
Q2 		$7.93M Buy
649,640
+83,661
+15% +$990K ﹤0.01% 3112
2022
Q1 		$8.12M Buy
565,979
+32,908
+6% +$538K ﹤0.01% 3264
2021
Q4 		$10.5M Buy
533,071
+2,829
+0.5% +$59.3K ﹤0.01% 3174
2021
Q3 		$11.5M Buy
530,242
+501,266
+1,730% +$14.4M ﹤0.01% 3158
2021
Q2 		$723K Buy
+28,976
New +$645K ﹤0.01% 4207

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group's JANX Position: Q4 2025 in Review

Vanguard Group increased its Janux Therapeutics (JANX) stake by 20% in Q4 2025, buying an estimated $11.5M and bringing the position to 2,906,386 shares worth $40.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

Vanguard Group first reported a position in JANX in Q2 2021 and has held it in 19 quarters since. The position peaked at $114M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Vanguard Group held 2,906,386 shares of Janux Therapeutics worth $40.1M as of Q4 2025.
  • Vanguard Group bought 489,282 Janux Therapeutics shares in Q4 2025, an estimated $11.5M.
  • Janux Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2287 holding.
  • Vanguard Group first reported a position in Janux Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Vanguard Group's Janux Therapeutics position peaked at $114M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.